Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 3, 1998, Pages 316-323

  Williamson, Kristin M ^b   Patterson, J Herbert ^b   McQueen, Robert H ^b   Adams Jr , Kirkwood F ^b   Pieper, John A ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; LOSARTAN; RIFAMPICIN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; HUMAN EXPERIMENT; LIVER; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; UNITED STATES; VOLUNTEER;

ADULT; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTIHYPERTENSIVE AGENTS; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMANS; IMIDAZOLES; LOSARTAN; MALE; REFERENCE VALUES; RIFAMPIN; TETRAZOLES; TIME FACTORS;

EID: 0031892332     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90163-1     Document Type: Article

References (24)

1. Physician's Desk Reference. 51st ed. Montvale (NJ): Medical Economics; 1997. p. 1668-70.
2. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 1996;156:1957-65.
3. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, et al. Nonpeptide angiotensin II receptor antagonists; XI: pharmacology of EXP3174 - an active metabolite of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255:211-7.
4. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-21.
5. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-7.
6. Stearns RA, Chakravarty PK, Chen R, Chiu SHL. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995;23:207-15.
7. Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP753) in human liver microsomes: role of cytochrome P4503A(4) in formation of the active metabolite E3174. Drug Metab Dispos 1995;23:285-9.
8. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121-6.
9. Wietholtz H, Zysset T, Marschall HU, Generet K, Matern S. The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 1995;22:78-81.
10. LeCluyse EL, Ribadeneira MD, Diamond S, Forster J, Huang SM, Madan A, et al. Induction of CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A by various drugs and prototypical inducers in primary cultures of human hepatocytes. Proceedings of the Seventh Annual Meeting of the North American International Society of the Study of Xenobiotics; San Diego, October 20-24, 1996.
11. Bachmann KA, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993;23:307-15.
12. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987;42:388-94.
13. Furtek CI, Lo MW. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr 1992;573:295-301.
14. Honig PK, Woosley RL, Zamani K, Conner D, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
15. Koselj M, Bren A, Kandus A, Kovac D. Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transpl Proc 1994;26:2823-4.
16. McCrea JB, Lo MW, Furtek CI, Ritter MA, Carides A, Waldman SA, et al. Ketoconazole does not effect the systemic conversion of losartan to E-3174 [abstract]. Clin Pharmacol Ther 1996;59:169.
17. Kazierad DJ, Martin DE, Tenero D, Boike SC, Ilson B, Freed MI, et al. Fluconazole significantly alters the pharmacokinetics of losartan but not eprosartan [abstract]. Clin Pharmacol Ther 1997;61:203.
18. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 1992;6:752-8.
19. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole; I: inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole - in vitro studies. Drug Metab Dispos 1996;24:414-21.
20. Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, McWilliams EJ, McCrea JB. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996;59:268-74.
21. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-indudble expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996;93: 4001-5.
22. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996;13:963-77.
23. Daniels NJ, Dover JS, Schachter RK. Interaction between cyclosporin and rifampicin [letter]. Lancet 1984;2:639.
24. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.